Skye Bioscience: which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
1 concentrated manager holds it with a median weight of 0.0%.
Who owns Skye Bioscience?
Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: Andrew J. Schwab (13D/A filed Aug 18, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were 5AM Venture Management (9.7 million shares), Versant Venture Management (2.0 million shares) and Baker Bros. Advisors (1.6 million shares).
Which institutions hold the most Skye Bioscience shares?
Per Form 13F filings as of Jun 30, 2026:
- 1. 5AM Venture Management: 9.7 million shares
- 2. Versant Venture Management: 2.0 million shares
- 3. Baker Bros. Advisors: 1.6 million shares
- 4. Vanguard Capital Management: 763,882 shares
- 5. Sphera Funds Management: 678,928 shares
- 6. Platinum Investment Management: 233,095 shares
- 7. BlackRock: 232,874 shares
- 8. Geode Capital Management: 218,055 shares
- 9. Millennium Management: 198,524 shares
- 10. Vanguard Fiduciary Trust: 104,229 shares
Sources:13D/A by Andrew J. Schwab (Aug 18, 2026) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Change in managers (1 → 1): 0 opened · 0 exited = 0
Net flow in the quarter: $0K (0 shares) · bought $0 and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
Concentrated managers holding it
- Baker Bros. Advisors$1.1M0.0%
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders (all 13F filers)
- 5AM Venture Management9.7 MPrivate equity or venture capital · 27.33% of the company0
- Versant Venture Management2.0 MPrivate equity or venture capital · 5.67% of the company0
- Baker Bros. Advisorsconcentrated1.6 MInvestment firm · 4.45% of the company0
- Vanguard Capital Management764 KIndex manager · 2.16% of the company−575
- Sphera Funds Management679 KInvestment firm · 1.92% of the company0
- Platinum Investment Management233 KType not verified · 0.66% of the company0
- BlackRock233 KIndex manager · 0.66% of the company−53 K
- Geode Capital Management218 KIndex manager · 0.62% of the company−59 K
- Millennium Management199 KQuant or multi-manager · 0.56% of the company−60 K
- Vanguard Fiduciary Trust104 KIndex manager · 0.29% of the company0
- Shares
- 9.7 M
- Change
- 0
- % of the company
- 27.33%
See more
- Type
- Private equity or venture capital
- Value
- $6.7M
- Versant Venture Management
- Shares
- 2.0 M
- Change
- 0
- % of the company
- 5.67%
See more
- Type
- Private equity or venture capital
- Value
- $1.4M
- Baker Bros. Advisorsconcentrated
- Shares
- 1.6 M
- Change
- 0
- % of the company
- 4.45%
See more
- Type
- Investment firm
- Value
- $1.1M
- Shares
- 764 K
- Change
- −575
- % of the company
- 2.16%
See more
- Type
- Index manager
- Value
- $529K
- Sphera Funds Management
- Shares
- 679 K
- Change
- 0
- % of the company
- 1.92%
See more
- Type
- Investment firm
- Value
- $471K
- Platinum Investment Management
- Shares
- 233 K
- Change
- 0
- % of the company
- 0.66%
See more
- Type
- Type not verified
- Value
- $162K
- Shares
- 233 K
- Change
- −53 K
- % of the company
- 0.66%
See more
- Type
- Index manager
- Value
- $161K
- Shares
- 218 K
- Change
- −59 K
- % of the company
- 0.62%
See more
- Type
- Index manager
- Value
- $151K
- Shares
- 199 K
- Change
- −60 K
- % of the company
- 0.56%
See more
- Type
- Quant or multi-manager
- Value
- $138K
- Shares
- 104 K
- Change
- 0
- % of the company
- 0.29%
See more
- Type
- Index manager
- Value
- $72.2K
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Fundamentals
12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.
- Operating margin
- —
- Net margin
- —
- ROE
- —
- Revenue (TTM)
- —
- Revenue growth
- —
- Net income (TTM)
- $-50.5M
- Net debt / EBITDA
- —
- Free cash flow (TTM)
- $-38.8M
- Quality vs sector
- —
This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Shares outstanding: buybacks and dilution
2025: 39.7 M
There is a jump that may be an undetected split: we do not show the changes.
- Buybacks (FY 2025)
- no data
- Share issuance
- no data
- Stock-based compensation
- $7.8M
- Dividends paid
- no data
From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.
Earnings quality and debt
- Operating cash flow ÷ net income (12 months)
- no datanot calculated with negative net income
- Interest coverage (operating income ÷ interest)
- no data
- Debt due within 12 months
- $143K0.01 times cash and investments
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- Andrew J. Schwab30.2%13D · amendmentfiling ↗Event: Aug 14, 2026 · filed: Aug 18, 2026
- Andrew J. Schwab34%13D · amendmentfiling ↗Event: Dec 12, 2025 · filed: Dec 16, 2025
- Schonfeld Strategic Advisors3.6%(fell below 5%)13G · amendmentfiling ↗Event: Jun 30, 2025 · filed: Aug 14, 2025
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Notice of delisting or failure to meet a listing rule (Item 3.01)
Notice of delisting or failure to meet a listing rule (Item 3.01)
Notice of delisting or failure to meet a listing rule (Item 3.01)
Change in directors or officers (Item 5.02)
Unregistered sale of equity securities (Item 3.02)
Unregistered sale of equity securities (Item 3.02)
Change in directors or officers (Item 5.02)
Change in directors or officers (Item 5.02)
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers